Fulcrum Therapeutics is a biopharmaceutical company developing drug candidates targeting genetically determined conditions with significant treatment gaps. The company's lead program, pociredir, is being tested in early-stage trials for sickle cell disease and beta-thalassemia by increasing fetal hemoglobin production, while its pipeline includes research programs addressing diamond-blackfan anemia, bone marrow failure disorders, and fibrotic conditions. The company operates under a licensing agreement with CAMP4 that provides access to small molecule compounds and related intellectual property for research and commercialization.
1Y: 3.79 (-49.7%) · range 3.14–14.60
entry readiness 47 · WEAK SETUP · exit proximity 0
Value area 3.16–3.94 · 34% of 120d volume overhead · moderate overhead
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +2.39% | +3.99% | mature |
| 40d | +1.06% | +3.99% | 35/40d |